Groupama Asset Managment Trims Stake in Exact Sciences Corporation

The institutional investor reduced its position in the medical research company by 0.8% during the third quarter.

Mar. 19, 2026 at 9:37am

Got story updates? Submit your updates here. ›

Groupama Asset Managment, an institutional investor, trimmed its position in Exact Sciences Corporation (NASDAQ:EXAS) by 0.8% during the third quarter, according to a disclosure filed with the Securities and Exchange Commission (SEC). The firm still owns 1,200,000 shares of the medical research company's stock, valued at approximately $65.65 million.

Why it matters

Institutional investors like Groupama Asset Managment closely monitor and adjust their positions in publicly traded companies. Changes in ownership stakes can provide insights into how these large investors view a company's prospects and performance.

The details

According to the SEC filing, Groupama Asset Managment sold 10,236 shares of Exact Sciences during the third quarter, reducing its total position to 1,200,000 shares. The firm now owns approximately 0.63% of Exact Sciences' outstanding stock.

  • Groupama Asset Managment trimmed its position in Exact Sciences during the third quarter of 2026.

The players

Groupama Asset Managment

An institutional investor that owns a stake in Exact Sciences Corporation.

Exact Sciences Corporation

A medical research company that develops diagnostic tests, including the Cologuard colorectal cancer screening test.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Groupama Asset Managment's position in Exact Sciences Corporation suggests the institutional investor may have a more cautious outlook on the medical research company's near-term prospects, though the firm still maintains a significant ownership stake.